{"id":"W4210686684","doi":"10.3324/haematol.2021.279520","title":"Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001)","year":2022,"lang":"en","type":"article","venue":"Haematologica","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; BC Children's Hospital; University of Toronto","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Children's Hospital of Philadelphia; U.S. Department of Defense; Rally Foundation; V Foundation for Cancer Research","keywords":"Medicine; Temsirolimus; Etoposide; Mucositis; Internal medicine; Gastroenterology; Cyclophosphamide; Leukemia; Leukopenia; Pharmacology; PI3K/AKT/mTOR pathway; Toxicity; Chemotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001088797,0.0006535032,0.001142081,0.0002816839,0.0001814077,0.0005537265,0.0004610184,0.0004693716,0.001216172],"category_scores_gemma":[0.0003921412,0.0002597889,0.0008373584,0.0004046745,0.00037963,0.0004350417,0.0003584409,0.001818306,0.0002145986],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000897318,"about_ca_system_score_gemma":0.001300422,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009522339,"about_ca_topic_score_gemma":0.00359885,"domain_scores_codex":[0.9997374,0.0001424295,0.00001908705,0.00003227578,0.00003441133,0.00003438],"domain_scores_gemma":[0.9997818,0.00002773038,0.00006557709,0.00001519013,0.00001317358,0.0000965066],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5462185,0.01964975,0.02286474,0.00216116,0.004524994,0.000733075,0.0004041866,0.007068035,0.04596191,0.00136426,0.01263262,0.3364167],"study_design_scores_gemma":[0.6596069,0.2477942,0.05670343,0.0002548495,0.00208254,0.001287674,0.0001414735,0.004375098,0.01016935,0.0005454975,0.01698909,0.00004988431],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920219,0.004253309,0.000287866,0.0005722964,0.00008716754,0.0005401698,0.0008096453,0.00007368045,0.001353926],"genre_scores_gemma":[0.9852641,0.005777495,0.002041615,0.001012564,0.0001887674,0.001088032,0.003057337,0.00002448566,0.001545718],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001216172,"threshold_uncertainty_score":0.006510556,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007659484694420746,"score_gpt":0.2440506352102129,"score_spread":0.2363911505157922,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}